AIRNA Announces $155M Series B Co-led by Venrock Healthcare and Forbion Growth

Gunderson Dettmer represented client AIRNA, an RNA editing company, in its $155 million Series B financing co-led by Venrock Healthcare Capital Partners and Forbion Growth. AIRNA’s lead program targets a liver and lung disease called alpha-1 antitryspin deficiency, or AATD.

The new capital will help AIRNA with further research and development as the company plans to file a clinical trial application by the second half of the year.

In the announcement of the transaction, AIRNA president and CEO Kris Elverum said, “Patients and physicians don’t want today’s one-and-supposedly-done therapies. Our RNA editing medicines are going to look and feel to patients and physicians like medicines that they’re used to.”

The Gunderson deal team was led by Kirt Shuldberg and Matthew Rietfors.

Companies
AIRNA
Venrock Healthcare Capital Partners
Forbion Growth